eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Novartis Pharmaceuticals UK Ltd

Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR
Telephone: +44 (0)1276 692 255
Fax: +44 (0)1276 698 449
Medical Information Direct Line: +44 (0)1276 698 370
Medical Information e-mail: medinfo.uk@novartis.com
Customer Care direct line: +44 (0)845 741 9442

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Patient Information Leaflet last updated on the eMC: 25/07/2011
PIL Sandostatin LAR

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 25/07/2011 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change to, or new, use for medicine
  • Change to dosage and administration
Updated on 18/05/2011 and displayed until 25/07/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 11/05/2010 and displayed until 18/05/2011
Reasons for adding or updating:
  • Change due to harmonisation of PIL.
  • Change to warnings or special precautions for use
Updated on 21/10/2009 and displayed until 11/05/2010
Reasons for adding or updating:
  • Change to Further Information section
Updated on 18/04/2008 and displayed until 21/10/2009
Reasons for adding or updating:
  • Transfer to upgraded management system
Updated on 07/02/2008 and displayed until 18/04/2008
Reasons for adding or updating:
  • Change due to user-testing of patient information
Updated on 28/11/2007 and displayed until 07/02/2008
Reasons for adding or updating:
  • Extra statutory information
Updated on 29/07/2004 and displayed until 28/11/2007
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 05/02/2004 and displayed until 29/07/2004
Reasons for adding or updating:
  • Update to PIL
Updated on 02/01/2001 and displayed until 05/02/2004
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   octreotide